|
E-mail this page to a friend!
Chronic Pain Market Driven by New Drugs and
Reformulations
Sales to grow to $24 billion in 2014 but NSAIDS,
COX-2 decline
Nov. 9, 2005 Senior citizens, who have faced a
dilemma in finding safe ways to treat their chronic pain, will be
turning to reformulations of existing drugs and some new drugs in the
years ahead, as the nonsteroidal anti-inflammatory drugs (NSAIDS) and
COX-2 inhibitors lose market share, according to a new report.
| |
Related Stories |
|
| |
Aspirin Taken with Another NSAID May Triple Risk for
Ulcers, Bleeding
Oct. 31, 2005 Senior citizens, who often take a
daily aspirin for cardiovascular protection and an occasional ibuprofen
or naproxen for pain relief, need to take heed of a study released today
that says combining the two significantly increases the risk of
gastrointestinal complications including ulcers, perforations and
bleeding. Read
more...
Senior Citizens May Have to Bite-the-Bullet for Pain
Relief
June
10, 2005 Senior citizens may have to bite-the-bullet, when it comes to
surviving pain, just like cowboys did in the old West movies, when the
doctor was about to operate without an anesthetic. There is a new
observational study out today that joins a list of those saying the risk
of heart attack, particularly in older people, increases with the use of
ibuprofen (Advil) and other commonly used painkillers, as well as COX-2
inhibitors. Read
more...
Oral Cancer Risk Cut in Half, Heart Risk Doubled by
Most NSAIDs
Oct. 7, 2005 - Aspirin only exception.
Another New Study Says Positive Thinking Can
Overcome Pain - Sept. 7, 2005
Older Osteoarthritis Patients Not Happy With
Alternative Therapy - July 29, 2005
Solution to COX-2 Inhibitor Dilemma May Be Massage
Cream - June 15, 2005
|
|
Therapies manufactured by Johnson & Johnson, Purdue
Pharma, Endo Pharmaceuticals, and Cephalon, will drive major market
sales from $15 billion in 2004 to more than $24 billion in 2014,
according to Decision Resources, Inc., a leading research and advisory
firm focusing on pharmaceutical and health care issues.
In addition, the new Pharmacor report entitled
Chronic Pain: Key Populations, Market Size, and the Driving Force of
Drug Reformulations finds that the antidepressant and antiepileptic
drug sectors will also experience significant growth over the next
decade as a result of new approvalsand thus more widespread usefor
chronic pain conditions.
Specifically, new drugs like duloxetine (Eli
Lilly's Cymbalta), DOV Pharmaceutical's bicifadine, pregabalin (Pfizer's
Lyrica), and new formulations of gabapentin (Pfizer's Neurontin,
generics) are expected to drive growth in the chronic pain market.
"NSAIDs and cyclooxygenase (COX)-2 inhibitors,
which accounted for nearly 50% of the chronic pain market in 2004, will
steadily lose market share in the wake of serious long-term safety
issues," said Michelle Grady, therapeutic area director, Pain, at
Decision Resources, Inc.
"Filling the void left by the declining use of
NSAIDs and COX- 2 inhibitors, opioid analgesics and antiepileptic drugs
will capture leading shares, together accounting for 55% of the chronic
pain therapy market in 2014, compared with a projected 18% NSAID/COX-2
market share that year."
About Chronic Pain
Key chronic pain populations include arthritic pain
(primarily osteoarthritis and rheumatoid arthritis pain), chronic low
back pain, cancer pain, prominent neuropathic pain conditions (i.e.,
painful diabetic neuropathy, postherpetic neuralgia, and HIV-related
neuropathic pain, fibromyalgia, and chronic headache.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that
assesses a host of market-impacting factors and analyzes the commercial
outlook for drugs in research and development.
About Decision Resources
Decision Resources, Inc., (www.decisionresources.com)
is a world leader in market research publications, advisory services,
and consulting designed to help clients shape strategy, allocate
resources, and master their chosen markets.
Click to More Senior News on the
Front Page
Copyright: SeniorJournal.com |
